시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
유방암 진단 시장 규모, 점유율, 성장 분석, 유형별, 제품별, 암 유형별, 용도별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)
Breast Cancer Diagnostics Market Size, Share, and Growth Analysis, By Type (Imaging, Biopsy), By Product (Platform-based Products, Instrument-based Products), By Cancer Type, By Application, By End-user, By Region - Industry Forecast 2025-2032
상품코드 : 1663027
리서치사 : SkyQuest
발행일 : 2025년 02월
페이지 정보 : 영문 219 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,300 ￦ 7,611,000
PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,200 ￦ 8,904,000
PDF & Excel (Multiple User License) help
PDF 및 Excel 보고서를 동일 사업장에서 2-5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,100 ￦ 10,197,000
PDF & Excel (Enterprise License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

유방암 진단 시장 규모는 2023년 56억 달러로 평가되었고, 예측 기간(2025-2032) 동안 7.8%의 연평균 복합 성장률(CAGR)로 2024년 60억 4,000만 달러에서 2032년에는 110억 1,000만 달러로 성장할 것으로 예상됩니다.

유방암 진단 시장은 감지 솔루션의 강화가 시급한 상황에서 빠르게 진화하고 있습니다. 유방암은 초기 증상이 나타나지 않는 경우가 많기 때문에 AI 기술은 환자 진단에 있어 매우 중요해지고 있으며, Paragon Biosciences LLC가 유방암 진단용 AI 시스템의 FDA 승인을 목표로 Qlarity Imaging LLC를 설립한 것이 그 한 예입니다. 다양한 영상 진단에 AI를 활용하는 기업들이 늘어나고 있으며, 의료 서비스 제공업체에게 비용 효율적인 솔루션을 제공합니다. 인도에서 후지필름의 건강검진센터인 NURA와 같은 민간 진단센터의 등장은 공공병원에 대한 접근성이 제한되어 있어 이를 대체할 수 있는 영상진단 서비스에 대한 수요 증가에 대응한 것입니다. 또한, 개발도상국에서는 지멘스, GE헬스케어, Philips 등의 고품질 재생의료 시스템 보급을 위한 업계의 노력에 힘입어 개조된 영상진단 장비가 비용 효율적인 대안으로 인기를 끌고 있습니다.

목차

서론

조사 방법

주요 요약

시장 역학과 전망

주요 시장 인사이트

유방암 진단 시장 규모 : 유형별

유방암 진단 시장 규모 : 제품별

유방암 진단 시장 규모 : 암 유형별

유방암 진단 시장 규모 : 용도별

유방암 진단 시장 규모 : 최종사용자별

유방암 진단 시장 규모

경쟁 정보

주요 기업 개요

결론과 제안

LSH
영문 목차

영문목차

Breast Cancer Diagnostics Market size was valued at USD 5.6 billion in 2023 and is poised to grow from USD 6.04 billion in 2024 to USD 11.01 billion by 2032, growing at a CAGR of 7.8% during the forecast period (2025-2032).

The breast cancer diagnostics market is evolving rapidly, driven by the urgent need for enhanced detection solutions. With breast cancer often presenting no early symptoms, AI technologies are becoming pivotal in addressing patient diagnostics, exemplified by Paragon Biosciences LLC's launch of Qlarity Imaging LLC, which aims for FDA clearance of an AI system for breast diagnostics. Companies are increasingly utilizing AI across various imaging modalities, presenting cost-effective solutions for healthcare providers. The rise of private diagnostic centers, like FUJIFILM Corporation's NURA in India, is a response to increased demand for imaging services, driven by public hospital limitations. Additionally, in developing regions, refurbished imaging equipment is gaining traction as a cost-effective alternative, supported by industry initiatives from Siemens, GE Healthcare, and Philips to promote quality refurbished systems.

Top-down and bottom-up approaches were used to estimate and validate the size of the Breast Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Breast Cancer Diagnostics Market Segments Analysis

Global Breast Cancer Diagnostics Market is segmented by Type, Product, Cancer Type, Application, End-user and region. Based on Type, the market is segmented into Imaging, Biopsy, Genomic Tests, Blood Tests and Others. Based on Product, the market is segmented into Platform-based Products and Instrument-based Products. Based on Cancer Type, the market is segmented into Ductal carcinoma in situ, Invasive ductal carcinoma, Inflammatory breast cancer and Metastatic breast cancer. Based on Application, the market is segmented into Screening, Diagnostic and Predictive, Prognostic, Research and Others. Based on End-user, the market is segmented into Hospitals & Clinics, Diagnostic Centers, Medical Laboratories and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Breast Cancer Diagnostics Market

The Breast Cancer Diagnostics market is primarily driven by technological advancements, including state-of-the-art imaging techniques, molecular diagnostic methods, and biomarker assays. These innovations have greatly enhanced the accuracy and efficiency of breast cancer detection and diagnosis, leading to their widespread adoption among healthcare professionals. The continuous development of sophisticated diagnostic tools not only improves patient outcomes but also propels market growth by meeting the increasing demand for reliable and effective breast cancer screening solutions. As these technologies evolve, they further reinforce the importance of early detection and timely intervention in combating breast cancer.

Restraints in the Breast Cancer Diagnostics Market

Cultural beliefs and the social stigma associated with breast cancer can significantly hinder women's willingness to participate in screening and diagnostic tests. These factors often lead to a reluctance to seek necessary medical attention, ultimately affecting the rates of early detection and diagnosis. As a result, many women might avoid or postpone crucial evaluations due to fear, misconceptions, or societal pressures. This resistance not only increases the risk of late-stage diagnosis but also poses a challenge to the overall effectiveness of breast cancer diagnostics in improving patient outcomes. Overcoming these barriers is essential for enhancing early intervention and promoting better health practices.

Market Trends of the Breast Cancer Diagnostics Market

The breast cancer diagnostics market is witnessing a significant trend towards the adoption of liquid biopsies, which analyze circulating tumor cells and cell-free DNA from blood samples. This non-invasive approach is particularly appealing for early detection and real-time monitoring of treatment efficacy, thereby enhancing patient outcomes. As healthcare providers and patients increasingly seek alternatives to traditional tissue biopsies, the demand for liquid biopsy solutions is surging. Coupled with advancements in molecular biology and personalized medicine, this trend is expected to drive innovation, investment, and growth within the breast cancer diagnostics landscape, positioning liquid biopsies as a cornerstone in future clinical practices.

Table of Contents

Introduction

Research Methodology

Executive Summary

Market Dynamics & Outlook

Key Market Insights

Global Breast Cancer Diagnostics Market Size by Type & CAGR (2025-2032)

Global Breast Cancer Diagnostics Market Size by Product & CAGR (2025-2032)

Global Breast Cancer Diagnostics Market Size by Cancer Type & CAGR (2025-2032)

Global Breast Cancer Diagnostics Market Size by Application & CAGR (2025-2032)

Global Breast Cancer Diagnostics Market Size by End-user & CAGR (2025-2032)

Global Breast Cancer Diagnostics Market Size & CAGR (2025-2032)

Competitive Intelligence

Key Company Profiles

Conclusion & Recommendations

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기